Deans' stroke musings: Do GLP-1 drugs reduce inflammation?

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Friday, February 27, 2026

Do GLP-1 drugs reduce inflammation?

What does your doctor think? Would they be useful in your recovery and prevention?

Do GLP-1 drugs reduce inflammation?

Q. In January 2025, you said that the new diabetes and weight-loss medications called GLP-1 drugs appeared to reduce the risk of many major diseases, by reducing inflammation. Do they still look so promising?

A. Even more so. In March 2025, a major new study was published in the journal Nature Medicine. The study involved nearly a million people with diabetes who took either GLP-1s or other diabetes medications and were followed for nearly a decade. Compared with those who didn’t take GLP-1s, those who did had a reduction of 10% to 20% in heart failure, cardiac arrest, lung failure, and pneumonia, and Alzheimer’s disease and other types of dementia. As with any drugs, some people experienced side effects, including stomach trouble, aching joints, and low blood pressure, but they were infrequent and relatively mild. Because these GLP-1s have been available for only a few years, we don’t yet know if long-term use will reveal additional adverse effects.

But this study and others linking medication with reduced inflammation continue to underline the importance of inflammation in several major diseases.